✦ LIBER ✦

Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes.

✍ Scribed by Brad R. Henke

Publisher: John Wiley and Sons
Year: 2004
Weight: 11 KB
Volume: 35
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200442238

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: α-Alkyl Substituted

ChemInform Abstract: α-Alkyl Substituted Pirinixic Acid Derivatives as Potent Dual Agonists of the Peroxisome Proliferator Activated Receptor α and γ.

✍ Oliver Rau; Yvonne Syha; Heiko Zettl; Michael Kock; Andreas Bock; Manfred Schube 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 24 KB 👁 1 views

Concise and Efficient Asymmetric Synthes

Concise and Efficient Asymmetric Synthesis of (S)-2-Ethylphenylpropanoic Acid Derivatives: Dual Agonists for Human Peroxisome Proliferator-Activated Receptor α and δ.

✍ Jun-ichi Kasuga; Yuichi Hashimoto; Hiroyuki Miyachi 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 22 KB 👁 1 views

ChemInform Abstract: Aleglitazar (I), a

ChemInform Abstract: Aleglitazar (I), a New, Potent, and Balanced Dual PPARα/γ Agonist for the Treatment of Type II Diabetes.

✍ Peter Mohr; et al. et al. 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 13 KB 👁 1 views

Reduction in the evolution of murine typ

Reduction in the evolution of murine type II collagen–induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator–activated receptor γ

✍ Salvatore Cuzzocrea; Emanuela Mazzon; Laura Dugo; Nimesh S. A. Patel; Ivana Serr 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB 👁 1 views

ChemInform Abstract: A Novel Series of (

ChemInform Abstract: A Novel Series of (S)-2,7-Substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists with Protein-Tyrosine Phosphatase 1B Inhibitory Activity.

✍ Kazuya Otake; Satoru Azukizawa; Masaki Fukui; Michiko Shibabayashi; Hikaru Kamem 📂 Article 📅 2012 🏛 John Wiley and Sons ⚖ 22 KB

Today's challenges and tomorrow's opport

Today's challenges and tomorrow's opportunities: ligands to peroxisome proliferator-activated receptors as therapies for type 2 diabetes and the metabolic syndrome

✍ Anne Reifel Miller 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB